Cargando…

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension

Pulmonary hypertension is a condition with limited effective treatment options. Chronic thromboembolic pulmonary hypertension (CTEPH) is a notable exception, with pulmonary endarterectomy (PEA) often proving curative. This study investigated the plasma metabolome of CTEPH patients, estimated reversi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swietlik, Emilia M., Ghataorhe, Pavandeep, Zalewska, Kasia I., Wharton, John, Howard, Luke S., Taboada, Dolores, Cannon, John E., Morrell, Nicholas W., Wilkins, Martin R., Toshner, Mark, Pepke-Zaba, Joanna, Rhodes, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012591/ https://www.ncbi.nlm.nih.gov/pubmed/33060150 http://dx.doi.org/10.1183/13993003.03201-2020

Ejemplares similares

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
por: Rhodes, Christopher J., et al.
Publicado: (2017)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension
por: Robertson, Lucy, et al.
Publicado: (2022)

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
por: Newnham, Michael, et al.
Publicado: (2019)

Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension
por: Harbaum, Lars, et al.
Publicado: (2019)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
por: Bunclark, Katherine, et al.
Publicado: (2021)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging
por: Attard, Mark I, et al.
Publicado: (2019)

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
por: Hadinnapola, Charaka, et al.
Publicado: (2015)

Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at follow‐up
por: Rodgers, Matthew S., et al.
Publicado: (2022)

Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
por: Rhodes, Christopher J, et al.
Publicado: (2017)

Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension
por: Jones, Rowena J., et al.
Publicado: (2022)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

Balloon pulmonary angioplasty outcomes in patients previously treated by pulmonary endarterectomy surgery are inferior to those of inoperable patients
por: Kirkby, Louise C., et al.
Publicado: (2023)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Maximal Cardiac Output Determines 6 Minutes Walking Distance in Pulmonary Hypertension
por: Deboeck, Gaël, et al.
Publicado: (2014)

Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
por: Rhodes, Christopher J., et al.
Publicado: (2020)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2021)

Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2022)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

Rising COVID-19 related acute pulmonary emboli but falling national chronic thromboembolic pulmonary hypertension referrals from a large national dataset
por: Newman, Joseph, et al.
Publicado: (2021)

The role of genomics and genetics in pulmonary arterial hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2020)

Ventriculo‐arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease
por: Axell, Richard G., et al.
Publicado: (2017)

Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesis
por: Belik, Daria, et al.
Publicado: (2016)

Endothelin ET(A) receptors predominate in chronic thromboembolic pulmonary hypertension
por: Southwood, Mark, et al.
Publicado: (2016)

Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021
por: Simonneau, Gérald, et al.
Publicado: (2023)

Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries
por: Schweikert, Bernd, et al.
Publicado: (2014)

COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey
por: Belge, Catharina, et al.
Publicado: (2020)

Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension
por: Heresi, Gustavo A., et al.
Publicado: (2020)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Metabolomic Profile in Venous Thromboembolism (VTE)
por: Franczyk, Beata, et al.
Publicado: (2021)

Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
por: Sofianopoulou, Eleni, et al.
Publicado: (2020)

Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials
por: Howard, Luke S. G. E., et al.
Publicado: (2021)

Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies
por: Grady, Duncan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i925sjn0n4o1hd59h6cldkl9qu